“…Within the therapeutic spectrum, laser therapy has been a cornerstone in managing both ischemic and nonischemic CRVO, primarily through procedures such as laser photocoagulation aimed at reducing macular edema and preventing neovascularisation. Despite its utility, the efficacy of laser photocoagulation in improving visual acuity in CRVO has been limited, contrasting its more pronounced benefits in cases of branch retinal vein occlusion (BRVO) [5,6]. The advent of pharmacological interventions, notably anti-VEGF agents, has heralded a paradigm shift in treatment approaches, offering new avenues for addressing the underlying pathophysiological mechanisms of CRVO [7][8][9].…”